From: Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada
Clinical Characteristics | HIV N = 2220 | HIV-HBV Co-Infected N = 199 | p valuea |
---|---|---|---|
Hepatitis C co-infection | 520 (23) | 61 (31) | 0.02 |
Baseline AST (IU/L) | 29 (23–41) | 36 (26–62) | < 0.0001 |
Baseline AST category | |||
 Normal (10–40 IU/L) | 1649 (74) | 120 (60) | < 0.0001 |
 Elevated (> 40 IU/L) | 571 (26) | 79 (40) | |
End of follow-up AST | 25 (20–33) | 26 (20–38) | 0.14 |
End of follow-up AST category | |||
 Normal (10–40 IU/L) | 1855 (84) | 152 (76) | 0.01 |
 Elevated (> 40 IU/L) | 365 (17) | 47 (24) | |
Baseline APRI | 0.37 (0.27–0.59) | 0.50 (0.35–1.04) | < 0.0001 |
Baseline APRI Fibrosis category | |||
  ≤ 0.5 (minimal) | 1501 (68) | 99 (50) | < 0.0001b |
 0.51–1.49 (moderate) | 593 (27) | 68 (34) | |
 1.50–1.99 (significant) | 34 (2) | 8 (4) | |
  ≥ 2.0 (advanced/cirrhosis) | 92 (4) | 24 (12) | |
End of follow-up APRI | 0.30 (0.22–0.43) | 0.32 (0.23–0.56) | 0.03 |
End of follow-up APRI Fibrosis category | |||
  ≤ 0.5 (minimal) | 1831 (82) | 145 (73) | 0.005b |
 0.51–1.49 (moderate) | 302 (14) | 39 (20) | |
 1.50–1.99 (significant) | 24 (1) | 3 (2) | |
  ≥ 2.0 (advanced/cirrhosis) | 63 (3) | 12 (6) |